-
2025-520861-29-00
5
Prostate cancer at risk of developing metastatic lesions
-
2025-520868-17-00
5
Cancer on the prostatic bed
-
2025-521037-86-00
5
Immune system diseases
-
2025-521038-27-00
5
Immune system diseases
-
2025-521113-13-00
10
Early Parkinson’s Disease
-
2025-521130-28-00
5
generalized myasthenia gravis
-
2025-521145-24-01
9
Active Idiopathic Inflammatory Myopathy including dermatomyositis, ant
-
2025-521154-42-00
4
Sickle Cell Disease
-
2025-521209-42-00
6
advanced colorectal cancer with wild-type RAS and right primary tumour
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-521390-14-00
4
Acute Myeloid Leukemia
-
2025-521583-35-00
4
non-small cell lung cancer (NSCLC)
-
2025-521587-35-00
5
Metastatic colorectal cancer
-
2025-521590-13-00
5
Moderately to Severely Active Crohn’s Disease
-
2025-521632-12-00
5
Patients on Factor Xa inhibitor treatment needing an urgent interventi
-
2025-521651-22-00
4
hormone receptor positive, HER2-negative breast cancer
-
2025-521671-31-00
9
Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+)
-
2025-521757-16-00
4
Hallucinations and Delusions Associated with Alzheimer’s Disease Psych
-
2025-521779-30-00
4
Geographic atrophy secondary to age-related macular degeneration
-
2025-521816-20-00
4
Exocrine Pancreatic Insufficiency
-
2025-521827-61-00
4
refractory/relapsed multiple myeloma
-
2025-521983-36-00
4
Colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenoc
-
2025-522019-40-00
9
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+)
-
2025-522084-15-00
10
metastatic NSCLC patients